BWAY News and Press, BrainsWay Ltd. From 07/25/19

HAVERHILL, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Achieve TMS East, Massachusetts’ largest provider of deep TMS therapy for the treatment of Depression and OCD, is pleased to announce the opening of its newest center in Haverhill, MA. Achieve TMS East will be celebrating the openin...

- First head-to-head, randomized controlled trial of its kind comparing Deep TMS, TMS and medication in depression patients published in July issue of the Journal of Psychiatric Research -    JERUSALEM, Israel and HACKENSACK, N.J., , July 18, 2019 (GLOBE NEWSWIRE) -- BrainsWay...

- First non-invasive device for OCD achieves 45% response rate among patients after one month follow up, and significantly reduced symptoms scores compared with placebo - HACKENSACK, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in th...

CHICAGO, June 27, 2019 (GLOBE NEWSWIRE) -- Dr. Fabian Carbonell  is the first psychiatrist in Chicago to offer patients with depression and obsessive-compulsive disorder the ability to be treated with  BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) therapy....

JERUSALEM and HACKENSACK, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay” or the “Company”), a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Comp...

JERUSALEM, Israel and HACKENSACK, N.J., June 17, 2019 (GLOBE NEWSWIRE) -- Brainsway Ltd. (NASDAQ & TASE: BWAY) (Brainsway), a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep ...

JERUSALEM and HACKENSACK, N.J., June 13, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay” or the “Company”), a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Comp...

CALABASAS, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- Calabasas Behavioral Health , a leading mental health service provider in Southern California, announced today that they are lending their time and expertise, in partnership with BrainsWay , the global leader in the advanced noninvasive...

Brainsway (NASDAQ: BWAY ): Q1 GAAP EPS of -$0.11. More news on: Brainsway Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

JERUSALEM and HACKENSACK, N.J., May 29, 2019 (GLOBE NEWSWIRE) -- Brainsway Ltd. (NASDAQ & TASE: BWAY) (“Brainsway” or the “Company”), a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using ...